Literature DB >> 23606238

The significance of heat shock proteins in breast cancer therapy.

Sevil Oskay Halacli1, Burcin Halacli, Kadri Altundag.   

Abstract

The evalutionary conserved heat shock proteins are involved basically life protecting mechanisms against harmful extracellular effects such as primarily heat shock response. Normally, the expression of these proteins is increased for cellular adaptation to high temperature. This increase is also important in the etiology of breast cancer. Overexpression of heat shock proteins is associated with reduced disease-free survival in breast cancer. However, increased expression of these proteins is related to acquired resistance of traditional chemotherapeutic drugs in use in breast cancer treatment. In this review, we discuss the multiple roles of heatshock proteins in resistance and where we are to overcome this in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23606238     DOI: 10.1007/s12032-013-0575-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  60 in total

1.  Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.

Authors:  Che-Hsin Lee; Hui-Mei Hong; Yu-Ying Chang; Wen-Wei Chang
Journal:  Biochimie       Date:  2012-03-15       Impact factor: 4.079

2.  Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells.

Authors:  R K Hansen; I Parra; P Lemieux; S Oesterreich; S G Hilsenbeck; S A Fuqua
Journal:  Breast Cancer Res Treat       Date:  1999-07       Impact factor: 4.872

Review 3.  Role of the major heat shock proteins as molecular chaperones.

Authors:  C Georgopoulos; W J Welch
Journal:  Annu Rev Cell Biol       Date:  1993

Review 4.  Design, synthesis, and evaluation of small molecule Hsp90 probes.

Authors:  Tony Taldone; Danuta Zatorska; Pallav D Patel; Hongliang Zong; Anna Rodina; James H Ahn; Kamalika Moulick; Monica L Guzman; Gabriela Chiosis
Journal:  Bioorg Med Chem       Date:  2011-03-12       Impact factor: 3.641

5.  Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.

Authors:  Nina Marie Pedersen; Inger Helene Madshus; Camilla Haslekås; Espen Stang
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

6.  Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.

Authors:  L M Vargas-Roig; F E Gago; O Tello; J C Aznar; D R Ciocca
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

7.  Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase.

Authors:  James W Antoon; Melyssa R Bratton; Lori M Guillot; Scott Wadsworth; Virgilio A Salvo; Steven Elliott; John A McLachlan; Matthew E Burow
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

8.  Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Authors:  Loreta M Rodrigues; Yuen-Li Chung; Nada M S Al Saffar; Swee Y Sharp; Laura E Jackson; Udai Banerji; Marion Stubbs; Martin O Leach; John R Griffiths; Paul Workman
Journal:  BMC Res Notes       Date:  2012-05-23

9.  Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.

Authors:  Qing Cheng; Jeffrey T Chang; Joseph Geradts; Leonard M Neckers; Timothy Haystead; Neil L Spector; H Kim Lyerly
Journal:  Breast Cancer Res       Date:  2012-04-17       Impact factor: 6.466

10.  Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.

Authors:  Se Hun Kang; Keon Wook Kang; Kyung-Hee Kim; Bumi Kwon; Seok-Ki Kim; Ho-Young Lee; Sun-Young Kong; Eun Sook Lee; Sang-Geun Jang; Byong Chul Yoo
Journal:  BMC Cancer       Date:  2008-10-04       Impact factor: 4.430

View more
  3 in total

1.  In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni.

Authors:  Bruno J Neves; Rodolpho C Braga; José C B Bezerra; Pedro V L Cravo; Carolina H Andrade
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

2.  STAT3 Target Genes Relevant to Human Cancers.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2014-04-16       Impact factor: 6.639

3.  Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland.

Authors:  Susanne B Breitkopf; Mateus De Oliveira Taveira; Min Yuan; Gerburg M Wulf; John M Asara
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.